Nondual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Before Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis
Journal of Cardiovascular Pharmacology April 1, 2024 Mengdi Zhang, Wenxing Peng, Shiqi Yin et al. 1 citation
For patients undergoing transcatheter aortic valve replacement (TAVR), avoiding dual antiplatelet therapy (DAPT) before the procedure reduces minor bleeding events without raising the risk of stroke or heart attack. A meta-analysis of 5 studies involving 2,329 patients found that preoperative non-DAPT (single antiplatelet therapy or none) was linked to a lower rate of minor bleeding compared with DAPT. Preoperative single antiplatelet therapy also lowered major bleeding risk. No significant differences were observed for other bleeding events, transfusions, stroke, heart attack, or death from any cause.